A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers

BioHealth Technologies

Status and phase: Completed; Phase 4

Conditions: Upper Respiratory Infections

Treatments: Other: PrevinC; Drug: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02225912

Previn-C

Details and patient eligibility

About

The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject must provide written informed consent prior to the conduct of any study
• Male or female
• 18-65 years of age
• Inclusive
• Employed by one of seven selected Day Care Centers

Exclusion criteria

• Recent symptoms of upper respiratory infection, respiratory disease
• Received medication for colds or allergies within 3 weeks of enrolling
• Had nasal surgery within 2 months of enrolling
• Had a pierced nose or wore nose jewelry

Trial design

0 participants in 2 patient groups, including a placebo group

PrevinC

Experimental group

Description:

PrevinC contains isopropyl alcohol, sesame oil, aloe vera oil extract, and lemon oil.

Treatment:

Other: PrevinC

Control solution

Placebo Comparator group

Description:

The control solution (distilled water and lemon oil) was similar in color, oily consistency and odor to that of PrevinC.

Treatment:

Drug: placebo